# Gland Pharma Q1 net jumps 47% to Rs 317 crore on revenue 2026-08-10T16:02:53+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet Gland Pharma reported a 47% year-on-year jump in consolidated net profit to Rs 317 crore for the June quarter, driven by a 20% rise in revenue to Rs 1,800.3 crore. Sequentially, net profit fell 14% while revenue inched up 3%. The company credited growth to new product launches from its CDMO portfolio and strong customer demand. The drugmaker also announced a strategic manufacturing and supply deal with a global pharma company covering a portfolio of sterile injectable products. The agreement spans 55 SKUs across three sites, with potential annualised revenue of $90-100 million once fully commercialised. Technology transfer is expected within two years, and revenue from the pact may begin only from calendar 2029. ## Coverage - thehindu.com Tags: BSE, CDMO, Gland Pharma, pharmaceuticals, Q1 earnings, sterile injectables Canonical: https://indianopinion.org/gland-pharma-q1-net-jumps-47-to-rs-317-crore-on-revenue/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/gland-pharma-q1-net-jumps-47-to-rs-317-crore-on-revenue/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.